Gelonghui May 17 丨 Shiyao Group (01093.HK) announced that the recombinant all-human anti-beta-Klotho monoclonal antibody drug (JMT202) developed by the Group has been approved by the China National Drug Administration and can conduct clinical trials in China.

This product is an FGFR1C/beta-Klotho receptor agonist. By binding to beta-Klotho protein, this product specifically activates the FGFR1C/beta-Klotho receptor complex, thereby simulating the effects of its natural ligand FGF21 protein and regulating glycolipid metabolism. This product can potentially be used to treat metabolism-related diseases such as dyslipidemia, non-alcoholic steatohepatitis (NASH), type 2 diabetes, and obesity, and has the potential to be used in combination with other target drugs (such as GLP-1) to regulate carbohydrate metabolism. The approved clinical indication is to reduce triglyceride (TG) levels in patients with hypertriglyceridemia. Preclinical studies have shown that this product has good safety and long dosing intervals, can significantly reduce triglycerides, and also has liver lipid-lowering effects, which is of great clinical development value.